Lonza maintains 2019 outlook after 'solid start' in Q1
Singapore
SWISS drug ingredients maker Lonza Group is maintaining its full-year outlook amid positive momentum in its core healthcare businesses and headwinds in its speciality ingredients segment, the company said in a business update provided on Thursday.
The company described the first quarter of 2019 as a "solid start" to the year. For the first three months, Lonza's newly formed pharma biotech and nutrition segment came in ahead of expectations compared to the same period a year ago, while its speciality ingredients segment performed below expectations, with sales on the same level as in the first three months of 2018, Lonza noted.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Singapore stocks end lower even as regional markets rally; STI slips 0.1%
New Thai finance minister downplays row with central bank
South-east Asia increasingly used for illicit money flows, terrorist financing: US Treasury official
Apac finance M&A to stay subdued after Q1 decline as uncertainties linger: S&P Global
Japan's Nikkei closes at 3-week high on US rate-cut outlook, tech boost
Philippines’ PLDT in talks to sell up to 49% of data centre business to Japan’s NTT